| Last modified date：2024.06.03 |
Lecturer /
Urology /
Kyushu University Hospital
Papers
| 1. | Ken Lee, Masaki Shiota, Dai Takamatsu, Miho Ushijima, Leandro Blas, Ayami Okabe, Shunichi Kajioka, Shunsuke Goto, Fumio Kinoshita, Takashi Matsumoto, Keisuke Monji, Eiji Kashiwagi, Junichi Inokuchi, Yoshinao Oda, Masatoshi Eto, Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy, Int J Urol, 10.1111/iju.15119. Epub 2022 Dec 7., 30(4):340-346, 2023.04. |
| 2. | Asako Machidori, Masaki Shiota, Satoshi Kobayashi, Takashi Matsumoto, Keisuke Monji, Eiji Kashiwagi, Ario Takeuchi, Ryosuke Takahashi, Junichi Inokuchi, Masatoshi Eto, Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors, Urol Oncol, 10.1016/j.urolonc.2020.09.036. Epub 2020 Oct 17., ;39(6):365.e1-365.e7, 2021.06. |
| 3. | Takashi Matsumoto, Masaki Shiota, Motonobu Nakamura, Akira Yokomizo, Toshihisa Tomoda, Naotaka Sakamoto, Narihito Seki, Shuji Hasegawa, Takakazu Yunoki, Masahiko Harano, Kentaro Kuroiwa, Masatoshi Eto, Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study, Prostate Int, 10.1016/j.prnil.2020.12.001. Epub 2020 Dec 30., 9(2):96-100, 2021.06. |
| 4. | Keisuke Monji, Takeshi Uchiumi, Saki Hoshizawa, Mikako Yagi, Takashi Matsumoto, Daiki Setoyama, Yuichi Matsushima, Kazuhito Gotoh, Rie Amamoto, Donchon Kang, Serum depletion induced cancer stem cell-like phenotype due to nitric oxide synthesis in oncogenic HRas transformed cells, ONCOTARGET, 10.18632/oncotarget.12117, 7, 46, 75221-75234, 2016.11. |
| 5. | Takashi Matsumoto, Takeshi Uchiumi, Keisuke Monji, Mikako Yagi, Daiki Setoyama, Rie Amamoto, Yuichi Matsushima, Masaki Shiota, Masatoshi Eto, Dongchon Kang, Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: importance of stem cell plasticity, ONCOGENESIS, 10.1038/s41389-017-0009-3, 6, 2017.11, Tumor heterogeneity can be traced back to a small subset of cancer stem cells (CSCs), which can be derived from a single stem cell and show chemoresistance. Recent studies showed that CSCs are sensitive to mitochondrial targeting antibiotics such as doxycycline. However, little is known about how cancer cells undergo sphere formation and how antibiotics inhibit CSC proliferation. Here we show that under sphere-forming assay conditions, prostate cancer cells acquired CSC-like properties: promoted mitochondrial respiratory chain activity, expression of characteristic CSC markers and resistance to anticancer agents. Furthermore, those CSC-like properties could reversibly change depending on the culture conditions, suggesting some kinds of CSCs have plasticity in tumor microenvironments. The sphere-forming cells (i.e. cancer stem-like cells) showed increased contact between mitochondria and mitochondrial associated-endoplasmic reticulum (ER) membranes (MAM). Mitochondrial targeting doxycycline induced activating transcription factor 4 (ATF4) mediated expression of ER stress response and led to p53-upregulated modulator of apoptosis (PUMA)-dependent apoptosis only in the cancer stem-like cells. We also found that doxycycline effectively suppressed the sphere formation in vitro and blocked CD44v9-expressing tumor growth in vivo. In summary, these data provide new molecular findings that monolayer cancer cells acquire CSC-like properties in a reversible manner. These findings provide important insights into CSC biology and a potential new treatment of targeting mitochondria dependency. . |
| 6. | Takashi Matsumoto, Masaki Shiota, Takeshi Uchiumi, Shohei Ueda, Shigehiro Tsukahara, Takahiro Toshima. Shinya Matsumoto, Nozomi Noda, Masatoshi Eto, Dongchon Kang, Genomic characteristics revealed by targeted exon sequencing of testicular germ cell tumors in Japanese men, international journal of urology, https://doi.org/10.1111/iju.14396, 2020.10, [URL]. |
| 7. | Masaki Shiota, Yohei Sekino, Shigehiro Tsukahara, Tatsuro Abe, Fumio Kinoshita, Kenjiro Imada, Shohei Ueda, Miho Ushijima, Shohei Nagakawa, Takashi Matsumoto, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Takeshi Uchiumi, Yoshinao Oda, Masatoshi Eto, Gene amplification of YB-1 in castration-resistant prostate cancer in association with aberrant androgen receptor expression, Cancer Sci, 10.1111/cas.14695. Epub 2020 Nov 24., 112(1):323-330, 2021.01. |
| 8. | Masaki Shiota, Naohiro Fujimoto, Takashi Matsumoto, Shigehiro Tsukahara, Shohei Nagakawa, Shohei Ueda, Miho Ushijima, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Takeshi Uchiumi, Masatoshi Eto, Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer, Front Oncol, 10.3389/fonc.2021.697955. eCollection 2021., 11:697955, 2021.05. |
| 9. | Mikifumi Koura, Masaki Shiota, Shohei Ueda, Takashi Matsumoto, Satoshi Kobayashi, Keisuke Monji, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken-Ichiro Shiga, Akira Yokomizo, Masatoshi Eto, Prognostic impact of prior local therapy in castration-resistant prostate cancer, Jpn J Clin Oncol, 10.1093/jjco/hyab019., 51(7):1142-1148, 2021.07. |
| 10. | Leandro Blas, Masaki Shiota, Shigetomo Yamada, Kosuke Ieiri, Shohei Nagakawa, Shigehiro Tsukahara, Takashi Matsumoto, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken-Ichiro Shiga, Akira Yokomizo, Masatoshi Eto, Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer, Anticancer Res, 10.21873/anticanres.15183., 41(8):3885-3889, 2021.08. |
| 11. | Shohei Nagakawa, Masaki Shiota, Naohiro Fujimoto, Yoshiaki Yamamoto, Leandro Blas, Shigehiro Tsukahara, Takashi Matsumoto, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Takeshi Uchiumi, Hideyasu Matsuyama, Masatoshi Eto, The impact of single-nucleotide polymorphisms on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer in a genome-wide association study, Urol Oncol, 10.1016/j.urolonc.2021.05.034. Epub 2021 Jun 29., 39(10):733.e17-733.e24, 2021.10. |
| 12. | Leandro Blas, Kosuke Ieiri, Masaki Shiota, Shohei Nagakawa, Shigehiro Tsukahara, Takashi Matsumoto, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken-Ichiro Shiga, Akira Yokomizo, Masatoshi Eto, Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer, Anticancer Res, 10.21873/anticanres.15373., 41(11):5593-5598, 2021.11. |
| 13. | Masaki Shiota, Leandro Blas, Satoshi Kobayashi, Takashi Matsumoto, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken-Ichiro Shiga, Akira Yokomizo, Masatoshi Eto, Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer, Int J Urol, 10.1111/iju.14702. Epub 2021 Sep 22., 29(1):26-32, 2022.01. |
| 14. | Takashi Matsumoto, Masaki Shiota, Shigetomo Yamada, Leandro Blas, Hidekazu Naganuma, Ken Lee, Keisuke Monji, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken-Ichiro Shiga, Akira Yokomizo, Masatoshi Eto, Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors, MA J, 10.31662/jmaj.2021-0163. Epub 2021 Dec 28., 5(1):83-90, 2022.01. |
| 15. | Hiroki Kobayashi, Masaki Shiota, Nobuaki Sato, Satoshi Kobayashi, Takashi Matsumoto, Keisuke Monji, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken-Ichiro Shiga, Akira Yokomizo, Masatoshi Eto, Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients, Anticancer Drugs, 10.1097/CAD.0000000000001170., 33(1):e541-e547, 2022.01. |
| 16. | Masaki Shiota, Naohiro Fujimoto, Yohei Sekino, Shigehiro Tsukahara, Shohei Nagakawa, Dai Takamatsu, Tatsuro Abe, Fumio Kinoshita, Shohei Ueda, Miho Ushijima, Takashi Matsumoto, Eiji Kashiwagi, Junichi Inokuchi, Takeshi Uchiumi, Yoshinao Oda, Masatoshi Eto , Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer, Andrologia, 10.1111/and.14307. Epub 2021 Nov 8., 54(1):e14307, 2022.02. |
| 17. | Sotaro Chikamatsu, Masaki Shiota, Shigetomo Yamada, Leandro Blas, Takashi Matsumoto, Eiji Kashiwagi, Junichi Inokuchi, Ken-Ichiro Shiga, Akira Yokomizo, Masatoshi Eto, Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer, Prostate Int, 10.1016/j.prnil.2022.01.001. Epub 2022 Jan 11., 10(1):7-13, 2022.03. |
| 18. | Shigehiro Tsukahara, Masaki Shiota, Dai Takamatsu\, Shohei Nagakawa, Takashi Matsumoto, Ryo Kiyokoba, Mikako Yagi, Daiki Setoyama, Nozomi Noda, Shinya Matsumoto, Tetsutaro Hayashi, Alberto Contreras-Sanz, Peter C Black, Junichi Inokuchi, Kenichi Kohashi, Yoshinao Oda, Takeshi Uchiumi, Masatoshi Eto, Dongchon Kang, Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine, Sci Rep, 10.1038/s41598-022-12528-3., 12(1):8535, 2022.05. |
| 19. | Shigetomo Yamada, Masaki Shiota, Leandro Blas, Takashi Matsumoto, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken-Ichiro Shiga, Akira Yokomizo, Masatoshi Eto, Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer, Prostate Int, 10.1016/j.prnil.2021.10.001. Epub 2021 Oct 30., 10(1):50-55, 2022.05. |
| 20. | Leandro Blas, Masaki Shiota, Shohei Nagakawa, Shigehiro Tsukahara, Takashi Matsumoto, Keisuke Monji, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Masatoshi Eto, Validation of models predicting lymph node involvement probability in patients with prostate cancer, Int J Urol, 10.1111/iju.14802. Epub 2022 Jan 31., 29(5):428-434, 2022.05. |
| 21. | Miho Ushijima, Masaki Shiota, Takashi Matsumoto, Eiji Kashiwagi, Junichi Inokuchi, Masatoshi Eto, An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer, Cancer Sci, 10.1111/cas.15280. Epub 2022 Apr 1., 113(5):1731-1738, 2022.05. |
| 22. | Eiji Kashiwagi, Masaki Shiota, Ken Lee, Keisuke Monji, Hidekazu Naganuma, Takashi Matsumoto, Ario Takeuchi, Junichi Inokuchi, Masatoshi Eto, Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide, JMA J, 10.31662/jmaj.2022-0096. Epub 2022 Sep 20., 5(4):491-497, 2022.10. |
| 23. | Eiji Kashiwagi, Masaki Shiota, Hidekazu Naganuma, Keisuke Monji, Kenjiro Imada, Ken Lee, Takashi Matsumoto, Ario Takeuchi, Junichi Inokuchi, Masatoshi Eto , Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer, Int J Urol, 10.1111/iju.14953. Epub 2022 Jun 18., 29(10):1155-1162, 2022.10. |
| 24. | Leandro Blas, Masaki Shiota, Dai Takamatsu, Fumio Kinoshita, Takashi Matsumoto, Ken Lee, Keisuke Monji, Eiji Kashiwagi, Junichi Inokuchi, Masatoshi Eto, Novel nomogram to predict biochemical recurrence-free survival after radical prostatectomy, World J Urol, 10.1007/s00345-022-04245-3. Epub 2022 Dec 17., 41(1):43-50, 2023.01. |
| 25. | Leandro Blas, Masaki Shiota, Shohei Nagakawa, Shigehiro Tsukahara, Takashi Matsumoto, Ken Lee, Keisuke Monji, Eiji Kashiwagi, Junichi Inokuchi, Masatoshi Eto, Validation of user-friendly models predicting extracapsular extension in prostate cancer patients, Asian J Urol, 10.1016/j.ajur.2022.02.008. Epub 2022 Apr 22., 10(1):81-88, 2023.01. |
| 26. | Matsumoto T, Hori Y, Shiota M, Blas L, Nakamura M, Seki N, Kuroiwa K, Yokomizo A, Morokuma F, Kiyoshima K, Eto M:, Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study., Int J Urol, Int J Urol 30(2):139-146, 2023, 2023.02. |
| 27. | Lee K, Shiota M, Takamatsu D, Ushijima M, Blas L, Okabe A, Kajioka S, Goto S, Kinoshita F, Matsumoto T, Monji K, Kashiwagi E, Inokuchi J, Oda Y, Eto M：, Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy., Int J Urol, Int J Urol 30(4):340-346, 2023, 2023.04. |
| 28. | Blas L, Shiota M, Tsukahara S, Nagakawa S, Matsumoto T, Eto M:, Adverse Events of Abiraterone Acetate vs Enzalutamide., Urol Pract, Urol Pract 10(4):361-370, 2023, 2023.07. |
| 29. | Blas L, Shiota M, Tsukahara S, Goto S, Kinoshita F, Matsumoto T, Monji K, Kashiwagi E, Inokuchi J, Eto M:, Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naïve men., Int J Urol, Int J Urol 30(7):600-604, 2023, 2023.07. |
| 30. | Shiota M, Ushijima M, Tsukahara S, Nagakawa S, Blas L, Takamatsu D, Kobayashi S, Matsumoto T, Inokuchi J, Eto M:, NR5A2/HSD3B1 pathway promotes cellular resistance to second-generation antiandrogen darolutamide., Drug Resist Updat, Drug Resist Updat 70:100990, 2023, 2023.09. |
| 31. | Kashiwagi E, Shiota M, Inokuchi J, Tsukahara S, Imada K, Monji K, Goto S, Matsumoto T, Eto M:, Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies., Anticancer Res, Anticancer Res 43(9):4249-4254, 2023, 2023.09. |
| 32. | Blas L, Shiota M, Matsumoto T, Hori Y, Nakamura M, Seki N, Kuroiwa K, Yokomizo A, Morokuma F, Kiyoshima K, Eto M:, Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment., Int J Urol, Int J Urol 30(11):1029-1034, 2023, 2023.11. |
| 33. | Shiota M, Tsukahara S, Ueda S, Mutaguchi J, Goto S, Kobayashi S, Matsumoto T, Blas L, Monji K, Inokuchi J, Eto M：, Improved urinary continence recovery after robot-assisted radical prostatectomy with lateral pelvic fascia preservation., J Robot Surg, J Robot Surg 17(6):2721-2728, 2023, 2023.12. |
| 34. | Shiota M, Tsukahara S, Takamatsu D, Tanegashima T, Ueda S, Blas L, Goto S, Kobayashi S, Matsumoto T, Inokuchi J, Shioyama Y, Eto M., Salvage robot-assisted radical prostatectomy after carbon ion radiotherapy to the prostate., Asian J Endosc Surg, Asian J Endosc Surg. 2024 Jan;17(1):e13279. doi: 10.1111/ases.13279., 2024.01. |
| 35. | Blas L, Shiota M, Tsukahara S, Nagakawa S, Matsumoto T, Eto M., Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab., Clin Genitourin Cancer, Clin Genitourin Cancer. 2024 Feb;22(1):e122-e127.e1. doi: 10.1016/j.clgc.2023.09.003. Epub 2023 Sep 18., 2024.02. |
Unauthorized reprint of the contents of this database is prohibited.